The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Corbus Pharmaceuticals presented new data from the first Western study of its antibody-drug conjugate treatment for cancer.

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...